Steadily Improving Survival in Lung Cancer

Dillman, Robert O.; McClure, Stephanie E.

doi:10.1016/j.cllc.2014.05.006

Cited by 21 publications

(26 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The improvement in the lung cancer survival rate may be related to several factors, including the introduction of the target agents [26], earlier diagnosis [27], and a decrease in surgical mortality [27]. The introduction of (neo)adjuvant chemotherapy contributed to the improvement of stages I-III resectable non-small cell lung cancer patients [28].…”

Section: Discussionmentioning

confidence: 99%

Lung Cancer Epidemiology in Korea

Shin

Kim

et al. 2017

Cancer Res Treat

View full text Add to dashboard Cite

PurposeThe current study was undertaken to examine the trends in the lung cancer incidence, mortality, and survival after a diagnosis in Korea.Materials and MethodsLung cancer incidence data according to the histologic type and mortality data were obtained from the Korea Central Cancer Registry and the Statistics Korea, respectively. The age-standardized incidence and mortality rates were calculated, and the Joinpoint model and age-period-cohort analyses were used to describe the trends in the rates. The 5-year relative survival rates of lung cancer were also calculated.ResultsAlthough the number of new lung cancer cases increased between 1999 and 2012, the age-standardized incidence rate decreased by 0.9% per year in men, whereas the incidence in women increased by 1.7% per year over the same time. Until 2010, the most common histologic type in men was squamous cell carcinoma, then adenocarcinoma prevailed thereafter. Since 1999, the most frequent histological type in women was adenocarcinoma. The lung cancer mortality started to decrease in 2002, with a more apparent decline for the younger age groups in both men and women. Overall, the 5-year relative survival rates have improved significantly from 11.2% for men and 14.7% for women among patients diagnosed between 1993 and 1997 to 19.3% for men and 28.2% for women among patients diagnosed between 2008 and 2012, respectively. An improvement in survival rate was observed for all major histology groups.ConclusionThe epidemiology of lung cancer in Korea has changed over a short time span, with decreasing mortality and improving survival rates. Further study is warranted to determine the cause of these changes.

show abstract

Section: Discussionmentioning

confidence: 99%

Lung Cancer Epidemiology in Korea

Shin

Kim

et al. 2017

Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…1 Despite diagnosis and therapeutic advances, the prognosis of lung cancer patients is still unsatisfactory. 2 To guide decision-making for therapeutic strategies for lung cancer patients and improve their prognosis, a better understanding of the relevant factors affecting lung cancer prognosis is urgently needed. In addition to some established indicator for survival, such as age, smoking status, histology, and stage, diabetes mellitus (DM) maybe another effective prognostic factors for lung cancer patients.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Diabetes Mellitus on Lung Cancer Prognosis

et al. 2016

View full text Add to dashboard Cite

Previous studies suggested that diabetes mellitus (DM) was associated with risk and mortality of cancer, but studies investigating the correlation between DM and lung cancer prognosis remain controversial. Herein, a meta-analysis was performed to derive a more precise estimate of the prognostic role of DM in lung cancer.Medline and Embase were searched for eligible articles from inception to October 25, 2015. The pooled hazard ratio (HR) with its 95% confidence interval (95% CI) was calculated to evaluate the correlation between DM and lung cancer prognosis. Subgroup meta-analysis was performed based on the histology and the treatment methods.A total of 20 cohort studies from 12 articles were included in the meta-analysis. Also, 16 studies investigated the overall survival (OS) and 4 studies investigated the progression-free survival (PFS). DM was significantly associated with the inferior OS of lung cancer with the pooled HR 1.28 (95% CI: 1.10–1.49, P = .001). The association was prominent in the nonsmall cell lung cancer (NSCLC) subgroup (HR 1.35, 95%CI: 1.14–1.60, P = .002), whereas the association was not significant in the small cell lung cancer (SCLC) subgroup (HR 1.33, 95% CI: 0.87–2.03, P = .18). When NSCLC patients were further stratified by treatment methods, DM had more influence on the surgically treated subgroup than the nonsurgically treated subgroup. There was no obvious evidence for publication bias by Begg's and Egger's test.The results of this meta-analysis exhibit an association of DM with inferior prognosis amongst lung cancer patients, especially the surgically treated NSCLC patients. Given the small number of studies included in this meta-analysis, the present conclusion should be consolidated with more high-quality prospective cohort studies or randomized controlled trials.

show abstract

“…These measures concerned cancer research, screening, and the medical and surgical management of NSCLC patients [6]. Few studies have used national databases to analyse the evolution of practices over a defined period [7,8], and few studies based on reports from institutions or the literature have been published [9][10][11]. It is difficult to interpret the findings because the data lack uniformity or come from single and/or specialised centres.…”

Section: Introductionmentioning

confidence: 99%

Time trends in surgery for lung cancer in France from 2005 to 2012: a nationwide study

Morgant

Pagès

Orsini³

et al. 2015

Eur Respir J

View full text Add to dashboard Cite

The aim of this study was to assess the evolution of survival in patients treated surgically for non-small cell lung cancer (NSCLC) between 2005 and 2012.From January 2005 to December 2012, 34 006 patients underwent pulmonary resection for NSCLC and were included in the French national database Epithor. Patients' characteristics, procedures and survival were analysed. Survival according to the management was evaluated for each 2-year period separately: 2005-2006, 2007-2008, 2009-2010 and 2011-2012.The proportions of early-stage cancers and adenocarcinomas increased significantly over the periods. 3-year overall survival (OS) increased significantly from 80.5% for the first period to 81.4% for the last period. For the periods 2005-2006 and 2007-2008, 3-year OS was lower after segmentectomy than after lobectomy (77 and 73% versus 82 and 83%, respectively). For the periods 2009-2010 and 2011-2012, 3-year OS in the two sub-groups was similar. OS after bi-lobectomy or pneumonectomy was lower than after lobectomy for all periods analysed. Systematic nodal dissection increased OS for all periods. Chemotherapy but not radiotherapy improved OS in the first 12 postoperative months for all periods.Changes in histological type and stage linked to advances in surgical and medical practices since 2005 led to an increase in OS in patients with surgical-stage NSCLC. @ERSpublications Overall survival and postoperative mortality after lung cancer surgery improve over the last decades

show abstract

Steadily Improving Survival in Lung Cancer

Cited by 21 publications

References 25 publications

Lung Cancer Epidemiology in Korea

Lung Cancer Epidemiology in Korea

The Effect of Diabetes Mellitus on Lung Cancer Prognosis

Time trends in surgery for lung cancer in France from 2005 to 2012: a nationwide study

Contact Info

Product

Resources

About